Basic Information

Gene symbol TNFRSF17 Synonyms BCM, BCMA, CD269, TNFRSF13A Type of gene protein-coding
Description TNF receptor superfamily member 17

GTO ID GTC0396
Trial ID NCT03338972
Disease Multiple Myeloma | Plasma Cell Myeloma
Altered gene BCMA
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment FCARH143
PhasePhase1
Recruitment statusCompleted
TitleImmunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Year2017
CountryUnited States
Company sponsorFred Hutchinson Cancer Center
Other ID(s)9762|NCI-2017-01932|9762|RG9217023|P01CA018029

Clinical Result

Cohort1: dose level 1
Administration route intravenous infusion
Dosage 50E6 cells/kg
Donor type Autologous
Pts 7
Age Adult, Older_Adult
Lymph depletion Yes
Outcome Dose-limiting Toxicities (DLT) Rate:0.0%; Count of Patients That Experienced Adverse Events:7
Adverse reactions 4/7(All-couse mortality); 5/7(Blood and lymphatic system disorders; General disorders; Infections and infestations; Vascular disorders)
Cohort2: dose level 2
Administration route intravenous infusion
Dosage 150E6 cells/kg
Donor type Autologous
Pts 8
Age Adult, Older_Adult
Lymph depletion Yes
Outcome Dose-limiting Toxicities (DLT) Rate:0.0%; Count of Patients That Experienced Adverse Events:8
Adverse reactions 3/8(All-couse mortality); 8/8(Blood and lymphatic system disorders; Gastrointestinal disorders; General disorders; Infections and infestations)
Cohort3: dose level 3
Administration route intravenous infusion
Dosage 300E6 cells/kg
Donor type Autologous
Pts 7
Age Adult, Older_Adult
Lymph depletion Yes
Outcome Dose-limiting Toxicities (DLT) Rate:14.3%; Count of Patients That Experienced Adverse Events:7
Adverse reactions 0/7(All-couse mortality); 5/7(Blood and lymphatic system disorders; General disorders; Immune system disorders; Renal and urinary disorders)
Cohort4: dose level 4
Administration route intravenous infusion
Dosage 450E6 cells/kg
Donor type Autologous
Pts 3
Age Adult, Older_Adult
Lymph depletion Yes
Outcome Dose-limiting Toxicities (DLT) Rate:0.0%; Count of Patients That Experienced Adverse Events:3
Adverse reactions 0/3(All-couse mortality); 3/3(Blood and lymphatic system disorders; General disorders)

Relationship Graph

Overview of Knowledge Graph